Back from ESC 2025 - and one thing was clear this year: the focus was on prevention.
New scientific findings and technological innovations are changing how we understand risk and act clinically.
Key takeaways:
- Inflammation & "invisible risk": hs-CRP is gaining importance as an independent predictor - especially in patients without classic risk factors.
- Genetics & PRS: Polygenic risk scores open up new ways of risk stratification, especially in younger patients.
- Imaging & AI: AI-based evaluation of routine CCTA significantly changes treatment decisions - with potential for personalized prevention
- New therapies: The focus is shifting from lipid management to targeted pathway modulation, for example via IL-6 and Lp(a).
- Adoption & integration: Evidence alone is not enough - embedding it in existing workflows is crucial.
Conclusion: Prevention is developing into a multi-layered approach comprising inflammation, genetics, imaging and AI. The next step: clear use cases and threshold values that enable doctors to act on a daily basis.
